Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr274.50 SEK
Change Today -5.00 / -1.79%
Volume 17.9K
BIOGB On Other Exchanges
Symbol
Exchange
OTC US
Berlin
Stockholm
As of 11:29 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

biogaia ab-b shs (BIOGB) Snapshot

Open
kr274.50
Previous Close
kr279.50
Day High
kr279.50
Day Low
kr274.00
52 Week High
05/22/15 - kr292.00
52 Week Low
10/13/14 - kr150.10
Market Cap
4.7B
Average Volume 10 Days
16.7K
EPS TTM
kr5.41
Shares Outstanding
16.5M
EX-Date
05/8/15
P/E TM
50.7x
Dividend
kr3.46
Dividend Yield
1.82%
Current Stock Chart for BIOGAIA AB-B SHS (BIOGB)

Related News

No related news articles were found.

biogaia ab-b shs (BIOGB) Related Businessweek News

No Related Businessweek News Found

biogaia ab-b shs (BIOGB) Details

BioGaia AB develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Paediatrics, Adult Health, and New Business segments. The company provides BioGaia ProTectis digestive health probiotic drops, as well as BioGaia ProTectis D3 drops with vitamin D3 containing lactobacillus reuteri protectis for children; and BioGaia ProTectis ORS, a probiotic oral rehydration solution with zinc. It also offers BioGaia ProTectis chewable tablet, a dietary supplement containing lactobacillus reuteri protectis, as well as BioGaia ProDentis oral lozenges, a dietary supplement containing lactobacillus reuteri prodentis for adults and children; BioGaia Gastrus, a probiotic supplement that could enhance treatment of Helicobacter pylori infection; and BioGaia ProTectis straw that provides lactobacillus reuteri protectis to various beverages. In addition, the company offers ProDentis oral health tablet for the treatment of periodontal disease and gingivitis; and component products, which are bacterial cultures of lactobacillus reuteri protectis that are used as ingredients in yoghurt and other dairy products. Further, it provides animal health products. The company sells its products through pharmacies and related outlets. BioGaia AB was founded in 1990 and is headquartered in Stockholm, Sweden.

98 Employees
Last Reported Date: 05/7/15
Founded in 1990

biogaia ab-b shs (BIOGB) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: kr2.3M
Compensation as of Fiscal Year 2014.

biogaia ab-b shs (BIOGB) Key Developments

BioGaia AB Approves Election of Board Members

BioGaia AB approved the election of Anthon Jahreskog and Ewa Björling as board members in the annual general meeting held on May 7, 2015. Anthon Jahreskog, born in 1980, Chief Operating Officer, Fund Linked Products, Credit Suisse Investment Bank, London. He has several years of experience from the international financial market and expertise in strategic business planning, cost efficiency and analysis. Anthon Jahreskog is independent of the company and its management and does not own any shares in BioGaia. Anthon Jahreskog does not serve any other boards. Ewa Björling, born in 1961, is a trained dentist and a Doctor of Medicine and senior lecturer in virology with many years of experience from Karolinska institutet. Ewa Björling has also been a member of the Riksdag and the Minister for Trade in the Swedish government from 2007 to 2014. Ewa Björling is independent of the company and its management and does not own any shares in BioGaia.

BioGaia AB Proposes Ordinary Dividend and an Extraordinary Dividend

The Board of Directors of BioGaia AB proposed that the forthcoming AGM be asked to approve an ordinary dividend of SEK 3.46 per share and an extraordinary dividend of SEK 1.54 per share, which makes a total dividend of SEK 5.00 per share. This will amount to a shareholders' dividend of SEK 86.4 million.

BioGaia AB Reports Consolidated and Parent Earnings Results for the First Quarter Ended March 31, 2015

BioGaia AB reported consolidated and parent earnings results for the first quarter ended March 31, 2015. For the quarter, on consolidated basis, the company’s net sales totalled SEK 138.3 million compared with SEK 93.2 million, an increase of SEK 45.6 million, this corresponds to a 49% rise, or 37% after adjustment for foreign exchange effects. Operating profit was SEK 52.6 million compared with SEK 28.4 million, an increase of SEK 24.2 million, this corresponds to an 85% rise, or 54% after adjustment for foreign exchange effects. Profit after tax was SEK 43.2 million compared with SEK 22.6 million, an increase of SEK 20.6 million or 91%. Earnings per share were SEK 2.50 compared with SEK 1.32 a year ago. Cash flow for the period was SEK 37.8 million compared with SEK 108.4 million. Profit before tax SEK 55,864,000 compared to SEK 124,656,000 a year ago. Cash flow from operating activities was SEK 43,375,000 compared to SEK 112,778,000 a year ago. Return on average equity was 12% compared to 27% a year ago. For the quarter, on parent basis, net sales in the parent company was SEK 134.5 million compared to SEK 88.9 million a year ago. Profit before tax was SEK 58.9 million compared to SEK 30.2 million a year ago. Negative cash flow in the parent company was SEK 27.6 million compared to SEK 105.8 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOGB:SS kr274.50 SEK -5.00

BIOGB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BLIS Technologies Ltd $0.02 NZD -0.001
Danone SA €62.58 EUR -0.64
Nestle SA SFr.72.15 CHF -0.70
Novartis AG SFr.96.30 CHF -1.10
Yakult Honsha Co Ltd ¥6,950 JPY +100.00
View Industry Companies
 

Industry Analysis

BIOGB

Industry Average

Valuation BIOGB Industry Range
Price/Earnings 51.2x
Price/Sales 11.1x
Price/Book 12.3x
Price/Cash Flow 49.0x
TEV/Sales 10.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGAIA AB-B SHS, please visit www.biogaia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.